



This is a repository copy of *The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/220597/>

Version: Supplemental Material

Article:

Mayor, N.P., Szydlo, R.M., Sheikh, Y. et al. (9 more authors) (2024) The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience. *The Lancet Haematology*, 11 (12). E916-E926. ISSN 2352-3026

[https://doi.org/10.1016/s2352-3026\(24\)00312-0](https://doi.org/10.1016/s2352-3026(24)00312-0)

© 2024 The Authors. Except as otherwise noted, this author-accepted version of a journal article published in *The Lancet Haematology* is made available via the University of Sheffield Research Publications and Copyright Policy under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.


Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Supplementary figure 1: A comparison of survival probability analysis between allogeneic haematopoietic cell transplant patients included in the study (ethnicity reported, red line) and those excluded due to missing ethnicity data (without ethnicity reported, blue line). This analysis suggests there were no demonstrable differences between the two cohorts of patients that may have skewed our findings. Numbers at the bottom of the graphs represent the number of at risk and censored (in parenthesis) patients.



Supplementary Table 1: Characteristics of the autologous transplant cohort

Variable	Autologous (N=20,119)				
	Overall N (%)	Asian N (%)	Black N (%)	Other N (%)	White N (%)
Number of patients by ethnicity	20,119	919 (5)	727 (4)	612 (3)	17,861 (88)
Patient age at transplant					
0-18	924 (5)	75 (8)	41 (6)	63 (10)	745 (4)
19-39	1,920 (9)	198 (22)	103 (14)	75 (12)	1,544 (9)
40-59	8,407 (42)	408 (44)	400 (55)	267 (44)	7,332 (41)
60+	8,868 (44)	238 (26)	183 (25)	207 (39)	8,240 (46)
Median (Range)	58 (0-78)	51 (0-74)	53 (0-76)	54 (0-75)	58 (0-78)
Patient sex					
Female	7,647 (38)	314 (34)	316 (43)	225 (37)	6,792 (38)
Male	12,419 (62)	605 (66)	408 (56)	386 (63)	11,020 (62)
Missing	53 (<1)	0	3 (<1)	1 (<1)	49 (<1)
Disease at transplant					
Multiple Myeloma	11,043 (55)	388 (42)	483 (66)	309 (50)	9,863 (55)
Hodgkin's Lymphoma	1,486 (7)	119 (13)	49 (7)	50 (8)	1,268 (7)
Non-Hodgkin's Lymphoma	5,441 (27)	260 (28)	106 (15)	141 (23)	4,934 (28)
Solid Tumours	1,149 (6)	85 (9)	37 (5)	64 (10)	963 (5)
Other Malignant	668 (3)	33 (4)	33 (4)	31 (5)	571 (3)
Autoimmune	310 (2)	29 (3)	13 (2)	14 (2)	254 (1)
Other non-malignant	22 (<1)	5 (<1)	6 (<1)	3 (<1)	8 (<1)
EBMT Stage					
Early	3,317 (16)	132 (14)	113 (16)	86 (14)	2,986 (17)
Intermediate	11,351 (56)	453 (49)	439 (60)	313 (51)	10,146 (57)
Advanced	3,391 (17)	192 (21)	92 (13)	108 (18)	2,999 (17)
Missing/undefined	2,060 (10)	142 (15)	83 (11)	105 (17)	1,730 (10)
Source of stem cells					
Bone Marrow	117 (<1)	6 (<1)	5 (<1)	6 (<1)	100 (<1)
PBSC	19,992 (99)	911 (99)	722 (99)	606 (99)	17,753 (99)
Missing	10 (<1)	2 (<1)	0	0	8 (<1)
Karnofsky Performance Score					
10-80	4,462 (22)	200 (22)	104 (14)	104 (17)	4,054 (23)
90-100	13,440 (67)	596 (65)	537 (74)	431 (70)	11,876 (66)
Missing/unknown	2,217 (11)	123 (13)	86 (12)	77 (13)	1,931 (11)
HCT-CI					
0	10,273 (51)	450 (49)	287 (39)	301 (49)	9,235 (52)
1-2	3,709 (18)	190 (21)	164 (23)	137 (22)	3,218 (18)
3+	2,184 (11)	94 (10)	95 (13)	54 (9)	1,941 (11)
Comorbid, HCT-CI unknown	1,677 (8)	86 (9)	105 (14)	54 (9)	1,432 (8)
Missing/unknown	2,276 (11)	99 (11)	76 (10)	66 (11)	2,035 (11)
Year of transplant					
2009	1,383 (7)	52 (6)	44 (6)	32 (5)	1,255 (7)
2010	1,562 (8)	53 (6)	53 (7)	28 (5)	1,428 (8)
2011	1,656 (8)	72 (8)	52 (7)	42 (7)	1,490 (8)
2012	1,734 (9)	88 (9)	69 (9)	36 (6)	1,541 (9)
2013	1,741 (9)	79 (9)	67 (9)	46 (8)	1,549 (9)
2014	1,784 (9)	84 (9)	50 (7)	41 (7)	1,609 (9)
2015	1,925 (10)	81 (9)	79 (11)	42 (7)	1,723 (10)
2016	2,035 (10)	88 (9)	66 (9)	66 (11)	1,815 (10)
2017	2,115 (11)	111 (12)	65 (9)	91 (15)	1,848 (10)
2018	2,079 (10)	106 (12)	84 (12)	98 (16)	1,791 (10)
2019	2,105 (11)	105 (11)	98 (13)	90 (15)	1,812 (10)
Follow-up					
Median (months)	60	56	60	48	61
Interquartile Range (months)	35-89	32-81	31-84	25-72	35-91

Supplementary Table 2a: Baseline characteristics of the allogeneic haematopoietic cell transplant cohort (N=13,978).

Variable	Allogeneic (N=13,978)				
	Overall N (%)	Asian N (%)	Black N (%)	Other N (%)	White N (%)
Number of patients by ethnicity	13,978 (100)	1,081 (8)	441 (3)	751 (5)	11,705 (84)
Patient age at transplant					
0-18	2,622 (19)	456 (42)	188 (43)	222 (30)	1,756 (15)
19-39	2,704 (20)	280 (26)	98 (22)	138 (18)	2,188 (19)
40-59	5,378 (38)	264 (24)	130 (30)	231 (31)	4,753 (40)
60+	3,274 (23)	81 (8)	25 (6)	160 (21)	3,008 (26)
Median (Range)	48 (0-76)	26 (0-72)	26 (0-68)	41 (0-76)	50 (0-76)
Donor age group					
0-10	214 (1.5)	63 (6)	28 (6)	24 (3)	99 (<1)
11-18	311 (2)	44 (4)	30 (7)	22 (3)	215 (2)
19-29	4,055 (29)	173 (16)	53 (12)	220 (29)	3,609 (31)
30-39	2,330 (17)	164 (15)	52 (12)	121 (16)	1,993 (17)
40-49	1,565 (11)	118 (11)	45 (10)	81 (11)	1,321 (11)
50-59	936 (7)	57 (5)	30 (7)	47 (6)	802 (7)
60+	443 (3)	24 (2)	5 (1)	13 (2)	401 (3)
Cord	683 (5)	110 (10)	70 (16)	64 (8)	439 (4)
Missing	3,441 (24.5)	328 (30)	128 (29)	159 (21)	2,826 (24)
Median (Range)	31 (0-82)	32 (0-70)	32 (0-70)	30 (2-70)	31 (0-82)
Patient sex					
Female	5,441 (39)	450 (42)	198 (45)	301 (40)	4,492 (38)
Male	8,519 (61)	628 (58)	242 (55)	449 (60)	7,200 (38)
Unknown	18 (<1)	3 (<1)	1 (<1)	1 (<1)	13 (<1)
Donor sex					
Female	4,671 (33)	425 (39)	202 (46)	282 (37)	3,762 (32)
Male	9,082 (65)	631 (59)	217 (49)	456 (61)	7,778 (67)
Missing	225 (2)	25 (2)	22 (5)	13 (2)	165 (1)
Donor/recipient sex match					
Male/Male	5,740 (41)	367 (34)	127 (29)	281 (37)	4,965 (42)
Male/Female	3,331 (24)	262 (24)	89 (20)	174 (23)	2,806 (24)
Female/Male	2,648 (19)	250 (23)	102 (23)	162 (22)	2,134 (18)
Female/Female	2,017 (14)	174 (16)	100 (23)	120 (16)	1,623 (14)
Missing	242 (2)	28 (3)	23 (5)	14 (2)	177 (2)
Disease at transplant					
Multiple Myeloma	342 (2)	15 (1)	10 (2)	12 (2)	305 (3)
Hodgkin's Lymphoma	542 (4)	48 (4)	16 (4)	26 (4)	452 (4)
Non-Hodgkin's Lymphoma	1,347 (10)	62 (6)	46 (10)	79 (10)	1,160 (10)
MDS	1,495 (11)	60 (6)	17 (4)	71 (10)	1,347 (11)
MPN	552 (4)	19 (2)	8 (2)	22 (3)	503 (4)
AML	4,801 (34)	261 (24)	110 (25)	227 (30)	4,203 (36)
ALL	1,795 (13)	166 (15)	58 (13)	95 (13)	1,476 (13)
CML	428 (3)	30 (3)	16 (4)	17 (2)	365 (3)
CLL	316 (2)	2 (<1)	3 (<1)	22 (3)	289 (3)
CMML	244 (2)	11 (1)	2 (<1)	10 (1)	221 (2)
Other Malignant	296 (2)	13 (1)	9 (2)	18 (2)	256 (2)
Aplastic Anaemia	806 (6)	104 (10)	26 (6)	52 (7)	624 (5)
Primary immune deficiencies	442 (3)	120 (11)	12 (3)	37 (5)	273 (2)
Other inherited disorders	169 (1)	50 (5)	1 (<1)	19 (3)	99 (<1)
Histiocytic disorders	77 (<1)	24 (2)	1 (<1)	8 (1)	44 (<1)
Haemoglobinopathies	225 (2)	84 (8)	98 (22)	29 (4)	14 (<1)
Autoimmune	36 (<1)	5 (<1)	2 (<1)	3 (<1)	26 (<1)
Other non-malignant	65 (<1)	7 (<1)	6 (1)	4 (<1)	48 (<1)
EBMT Stage					
Early	4,575 (33)	222 (20)	98 (22)	209 (28)	4,046 (35)
Intermediate	3,172 (23)	179 (17)	76 (17)	145 (19)	2,772 (24)
Advanced	3,003 (21)	241 (22)	99 (22)	173 (23)	2,490 (21)

Variable	Allogeneic (N=13,978)				
	Overall N (%)	Asian N (%)	Black N (%)	Other N (%)	White N (%)
Missing/undefined	3,228 (23)	439 (41)	168 (38)	224 (30)	2,397 (20)
Donor type					
Volunteer Unrelated Donor	8,540 (61)	323 (30)	96 (22)	392 (52)	7,729 (66)
Related donor	4,261 (30.5)	539 (50)	197 (45)	220 (29)	3,306 (28)
Haploidentical	495 (3.5)	109 (10)	78 (18)	75 (10)	231 (2)
Umbilical Cord Blood	683 (5)	110 (10)	70 (16)	64 (8)	439 (4)
HLA match					
10/10 HLA matched RD	4,152 (30)	519 (48)	193 (44)	207 (28)	3,233 (28)
9/10 HLA matched RD	29 (<1)	3 (<1)	1 (<1)	1 (<1)	24 (<1)
≤8/10 HLA matched RD	48 (<1)	8 (<1)	1 (<1)	7(1)	32 (<1)
10/10 HLA matched VUD	5,744 (41)	146 (14)	31 (7)	239 (32)	5,328 (46)
9/10 HLA matched VUD	1,410 (10)	103 (10)	34 (8)	85 (11)	1,188 (10)
≤8/10 HLA matched VUD	218 (2)	18 (2)	13 (3)	11 (1)	176 (2)
10/10 HLA matched Cord	86 (<1)	20 (2)	5 (1)	2 (<1)	59 (<1)
9/10 HLA matched Cord	41 (<1)	4 (<1)	2 (<1)	6 (<1)	29 (<1)
≤8/10 HLA matched Cord	117 (<1)	19 (2)	16 (4)	21 (3)	61 (<1)
9/10 HLA matched Haploidentical/MMRD	38 (<1)	5 (<1)	4 (1)	2 (<1)	27 (<1)
8/10 HLA matched Haploidentical/MMRD	183 (1)	51 (5)	44 (10)	24 (3)	64 (<1)
≤7/10 HLA matched Haploidentical/MMRD	242 (2)	47 (4)	27 (6)	38 (5)	130 (1)
Indeterminable match	147 (1)	20 (2)	10 (2)	21 (3)	96 (<1)
Missing	1,523 (11)	118 (11)	60 (14)	87 (12)	1,258 (11)
Source of stem cells					
Bone Marrow	1,896 (14)	260 (24)	129 (29)	129 (17)	1,378 (12)
PBSC	11,370 (81)	709 (66)	237 (53)	556 (74)	9,868 (84)
Bone Marrow + PBSC	21 (<1)	2 (<1)	2 (<1)	2 (<1)	15 (<1)
Umbilical Cord Blood	683 (5)	110 (10)	70 (16)	64 (8)	439 (4)
Missing	8 (<1)	0	3 (<1)	0	5 (<1)
Donor/recipient CMV serostatus match					
Positive/Positive	4,439 (32)	629 (58)	237 (54)	325 (43)	3,248 (28)
Positive/Negative	1,318 (9)	117 (11)	41 (9)	58 (8)	1,102 (9)
Negative/Positive	2,411 (17)	159 (15)	74 (19)	120 (16)	2,058 (18)
Negative/Negative	5,262 (38)	124 (11)	60 (14)	198 (26)	4,880 (42)
Missing	548 (4)	52 (5)	29 (7)	50 (7)	417 (4)

Matched	9,701 (72)	753 (73)	297 (72)	523 (75)	8,128 (72)
Mismatched	3,729 (28)	276 (27)	115 (28)	178 (25)	3,160 (28)
Karnofsky Performance Score					
≤70	858 (6)	57 (5)	21 (5)	32 (4)	748 (6)
80	2,032 (15)	129 (12)	67 (15)	85 (11)	1,751 (15)
90	5,981 (43)	352 (33)	167 (38)	310 (41)	5,152 (44)
100	3,667 (26)	335 (31)	122 (28)	246 (33)	2,964 (25)
Missing	1,440 (10)	208 (19)	64 (15)	78 (10)	1,090 (9)
Conditioning regimen					
Myeloablative	4,808 (35)	562 (52)	243 (55)	291 (39)	3,712 (32)
RIC	8,995 (64)	480 (44)	190 (43)	437 (58)	7,888 (67)
Missing	175 (1)	39 (4)	8 (2)	23 (3)	105 (1)
T cell depletion					
Alemtuzumab	8,181 (58)	461 (43)	136 (31)	315 (42)	7,269 (62)
ATG or ALG	2,177 (16)	197 (18)	121 (27)	105 (14)	1,754 (15)
No	3,620 (26)	423 (39)	184 (42)	331 (44)	2,682 (23)
HCT-CI					
0	6,275 (45)	482 (45)	179 (41)	350 (47)	5,264 (45)
1-2	2,827 (20)	224 (21)	99 (22)	154 (20)	2,350 (20)
3+	1,968 (14)	132 (12)	58 (13)	62 (8)	1,716 (15)
Missing	2,908 (21)	243 (22)	105 (24)	185 (25)	2,375 (20)
Prior autologous transplant					
No	13,048 (93)	1,041 (96)	421 (96)	719 (96)	10,867 (93)
Yes	930 (7)	40 (4)	20 (4)	32 (4)	838 (7)

Variable	Allogeneic (N=13,978)				
	Overall N (%)	Asian N (%)	Black N (%)	Other N (%)	White N (%)
Year of transplant					
2009	983 (7)	69 (6)	22 (5)	29 (4)	863 (7)
2010	1,050 (8)	71 (7)	24 (5)	32 (4)	923 (8)
2011	1,188 (9)	88 (8)	27 (6)	45 (6)	1,028 (9)
2012	1,236 (9)	99 (9)	35 (8)	53 (7)	1,049 (9)
2013	1,322 (10)	101 (9)	49 (11)	49 (6)	1,123 (10)
2014	1,381 (10)	112 (10)	51 (12)	60 (8)	1,158 (10)
2015	1,330 (9)	103 (9)	46 (10)	58 (7)	1,123 (10)
2016	1,391 (10)	126 (12)	52 (12)	134 (18)	1,079 (9)
2017	1,373 (10)	113 (11)	49 (11)	103 (14)	1,108 (9)
2018	1,326 (9)	84 (8)	43 (10)	80 (11)	1,119 (10)
2019	1,398 (10)	115 (11)	43 (10)	108 (14)	1,132 (10)
Follow-up					
Median (months)	32	36	35	29	31
Interquartile Range (months)	10-68	10-70	12-66	9-60	10-68

Supplementary Table 2b: Additional characteristics of the allogeneic haematopoietic cell transplant adult (N=11,488) and paediatric (N=2,490) cohorts. This data supplements the information in Table 1.

Variable	Adult Allo-HCT cohort (N=11,488)					Paediatric Allo-HCT cohort (N=2,490)				
	Overall N (%)	Asian N (%)	Black N (%)	Other N (%)	White N (%)	Overall N (%)	Asian N (%)	Black N (%)	Other N (%)	White N (%)
Number of patients by ethnicity	11,488	637	262	536	10,053	2,490	444	179	215	1,652
Donor/recipient sex match										
Male/Male	4,817 (42)	227 (36)	77 (29)	206 (38)	4,307 (43)	923 (37)	140 (32)	50 (28)	75 (35)	658 (40)
Male/Female	2,744 (24)	153 (24)	47 (18)	123 (23)	2,421 (24)	587 (23)	109 (24)	42 (23)	51 (24)	385 (23)
Female/Male	2,134 (19)	146 (23)	61 (23)	107 (20)	1,820 (18)	514 (21)	104 (24)	41 (23)	55 (26)	314 (19)
Female/Female	1,623 (14)	96 (15)	62 (24)	93 (17)	1,372 (14)	394 (16)	78 (17)	38 (21)	27 (12)	251 (15)
Missing	170 (1)	15 (2)	15 (6)	7 (1)	133 (1)	72 (3)	13 (3)	8 (4)	7 (3)	44 (3)
Disease at transplant										
Multiple Myeloma	342 (3)	15 (2)	10 (4)	12 (2)	305 (3)	0	0	0	0	0
Hodgkin's Lymphoma	523 (5)	46 (7)	15 (6)	26 (5)	436 (4)	19 (1)	2 (<1)	1 (<1)	0	16 (1)
Non-Hodgkin's Lymphoma	1,297 (11)	53 (8)	42 (16)	76 (14)	1,126 (11)	50 (2)	9 (2)	4 (2)	3 (1)	34 (2)
MDS	1,428 (12)	52 (8)	13 (5)	69 (13)	1,294 (13)	67 (3)	8 (2)	4 (2)	2 (1)	53 (3)
MPN	1,428 (12)	19 (3)	8 (3)	22 (4)	503 (5)	0	0	0	0	0
AML	552 (5)	229 (36)	92 (35)	190 (35)	3861 (38)	429 (17)	32 (7)	18 (10)	37 (17)	342 (21)
ALL	4,372 (38)	124 (20)	37 (14)	58 (11)	1,096 (11)	480 (19)	42 (10)	21 (12)	37 (17)	380 (23)
CML	1,315 (11)	30 (5)	16 (6)	17 (3)	365 (4)	0	0	0	0	0
CLL	316 (3)	2 (<1)	3 (1)	22 (4)	289 (3)	0	0	0	0	0
CMML	198 (2)	9 (1)	2 (1)	6 (1)	181 (2)	46 (2)	2 (<1)	0	4 (2)	40 (2)
Other Malignant	230 (2)	7 (1)	6 (2)	10 (2)	207 (2)	66 (3)	6 (1)	3 (2)	8 (4)	49 (3)
Aplastic Anaemia	422 (4)	44 (7)	12 (5)	24 (5)	342 (3)	384 (15)	60 (14)	14 (8)	28 (13)	282 (17)
Primary immune deficiencies	0	0	0	0	0	442 (18)	120 (27)	12 (7)	37 (17)	273 (17)
Other inherited disorders	0	0	0	0	0	169 (7)	50 (11)	1 (<1)	19 (9)	99 (6)
Histiocytic disorders	0	0	0	0	0	77 (3)	24 (5)	1 (<1)	8 (4)	44 (3)
Haemoglobinopathies	0	0	0	0	0	225 (9)	84 (19)	98 (55)	29 (14)	14 (1)
Autoimmune	0	0	0	0	0	36 (1)	5 (1)	2 (1)	3 (1)	26 (2)
Other non-malignant	65 (<1)	7 (1)	6 (2)	4 (1)	48 (<1)	0	0	0	0	0
EBMT Stage										
Early	4,325 (38)	205 (32)	87 (33)	192 (36)	3,841 (38)	250 (10)	17 (4)	11 (6)	17 (8)	205 (12)

Intermediate	2,708 (24)	139 (22)	59 (23)	106 (20)	2,404 (24)	464 (19)	40 (9)	17 (9)	39 (18)	368 (22)
Advanced	2,672 (23)	205 (32)	79 (30)	150 (28)	2,238 (22)	331 (13)	36 (8)	20 (11)	23 (11)	252 (15)
Missing/undefined	1,783 (15)	88 (14)	37 (14)	88 (16)	1,570 (16)	1,445 (58)	351 (79)	131 (73)	136 (63)	827 (50)
Donor/recipient CMV serostatus match										
Positive/Positive	3,891 (34)	440 (69)	161 (62)	251 (47)	3,039 (30)	548 (22)	189 (43)	76 (43)	74 (34)	209 (13)
Positive/Negative	2,050 (18)	100 (16)	50 (19)	97 (18)	1,803 (18)	361 (15)	59 (13)	24 (13)	23 (11)	255 (15)
Negative/Positive	997 (9)	35 (5)	14 (5)	20 (4)	928 (9)	321 (13)	82 (18)	27 (15)	38 (18)	174 (11)
Negative/Negative	4,148 (36)	37 (6)	21 (8)	136 (25)	3,954 (39)	1,114 (45)	87 (20)	39 (22)	62 (29)	926 (56)
Missing	402 (3)	25 (4)	5 (6)	32 (6)	329 (3)	146 (6)	27 (6)	13 (7)	18 (8)	88 (5)

Matched	8,039 (70)	477 (75)	181 (69)	387 (72)	6,993 (70)	1662 (67)	276 (62)	115 (64)	136 (63)	1,135 (69)
Mismatched	3,047 (26)	135 (21)	64 (24)	117 (22)	2,731 (27)	682 (27)	141 (32)	51 (29)	40 (22)	429 (26)
Prior autologous transplant										
No	10,567 (92)	597 (94)	242 (92)	505 (94)	9,223 (92)	2481 (100)	444 (100)	179 (100)	214 (100)	1,644 (100)
Yes	921 (8)	40 (6)	20 (8)	31 (6)	830 (8)	9 (<1)	0	0	1 (<1)	8 (<1)

Supplementary table 3: HLA matching and donor sources of the allogeneic haematopoietic cell transplant cohort.

HLA match	Related donor N, (%)	Unrelated donor N, (%)	Cord blood N, (%)	Mismatched Related or Haploidentical donor N, (%)
10/10	4,152 (97)	5,744 (67)	86 (13)	0
9/10	29 (<1)	1,410 (17)	41 (6)	38 (8)
8/10	6 (<1)	169 (2)	57 (8)	183 (38)
7/10	4 (<1)	27 (<1)	34 (5)	24 (5)
6/10	10 (<1)	14 (<1)	19 (3)	61 (13)
5/10 or lower	28 (<1)	8 (<1)	7 (1)	157 (32)
Indeterminable	19 (<1)	47 (<1)	57 (8)	24 (5)
Missing	20 (<1)	1,121 (13)	382 (56)	0

Supplementary Table 4a: Multivariate analysis for 5-year Overall Survival in the different autologous HCT subgroups – adult patients

Variable	Overall cohort (N=19,197)			Malignant disease cohort (N=18, 884)			Non-Malignant disease cohort (N=313)		
	No. cases	HR (95% CI)	P	No. cases	HR (95% CI)	P	No. cases	HR (95% CI)	P
Patient ethnicity			0.89			0.92			0.29
Asian	849	0.96 (0.84-1.10)	0.57	818	0.96 (0.84-1.10)	0.57	31	1.41 (0.15-13.5)	0.76
Black	684	1.11 (0.96-1.27)	0.15	670	1.10 (0.96-1.27)	0.17	14	4.49 (0.73-27.5)	0.11
Other	549	0.97 (0.82-1.15)	0.70	535	0.96 (0.81-1.14)	0.67	14	/	0.22
White	17,115	1.0		16,861	1.0		254	1.0	
Karnofsky Performance Score			0.041			0.039			0.98
100	4,522	1.0		4,508	1.0		22	1.0	
90	8,503	1.06 (0.99-1.13)	0.072	8,444	1.06 (1.00-1.13)	0.066	59	0.33 (0.04-2.71)	0.301
80	3,134	1.19 (1.10-1.29)	<0.0001	3,043	1.19 (1.10-1.29)	<0.0001	91	0.21 (0.03-1.29)	0.104
≤70	1,116	1.48 (1.32-1.66)	<0.0001	997	1.49 (1.33-1.67)	<0.0001	119	0.23 (0.04-1.44)	0.12
missing	1,922	1.17 (1.07-1.29)	0.0010	1,900	1.17 (1.07-1.29)	0.00088	22	0.46 (0.03-6.61)	0.57
HCT-CI			0.005			0.0054			0.65
Unknown	1,650	1.0		1,607	1.0		43	0.17 (0.02-1.49)	0.11
None	9,657	0.87 (0.80-0.96)	0.0040	9,506	0.88 (0.80-0.96)	0.0046	151	0.80 (0.11-5.80)	0.82
Low	3,672	0.97 (0.88-1.08)	0.62	3,595	0.97 (0.88-1.08)	0.61	77	0.71 (0.06-8.34)	0.78
Intermediate/High	2,162	1.06 (0.95-1.19)	0.28	2,132	1.06 (0.95-1.19)	0.27	30	0.76 (0.07-8.73)	0.83
Missing	2,056	0.94 (0.84-1.05)	0.27	2,044	0.94 (0.84-1.05)	0.27	12	1.0	
Diagnosis									
HL	1,431	0.62 (0.54-0.72)	<0.0001	1,431	0.62 (0.54-0.72)	<0.0001			
NHL	5,403	1.18 (1.11-1.25)	<0.0001	5,403	1.18 (1.11-1.25)	<0.0001			
Solid tumours	383	3.54 (2.97-4.22)	<0.0001	383	3.54 (2.98-4.22)	<0.0001			
Other malignant	662	0.69 (0.58-0.81)	<0.0001	662	0.69 (0.58-0.81)	<0.0001			
MM	11,005	1.0		11,005	1.0				
Non-malignant	307	0.17 (0.10-0.32)	<0.0001						
Patient sex									
Male	11,920	1.18 (1.12-1.24)	<0.0001	11,778	1.18 (1.12-1.24)	<0.0001	142	1.52 (0.40-5.80)	0.54
Female	7,277	1.0		7106	1.0		171	1.0	
Patient age			<0.0001			<0.0001			0.088
18-29	903	1.0		849	1.0		54		
30-39	1,067	1.09 (0.90-1.33)	0.37	976	1.09 (0.90-1.33)	0.22	91		
40-49	2,612	1.17 (0.97-1.41)	0.10	2,510	1.18 (0.97-1.42)	0.030	102		
50-59	5,773	1.42 (1.18-1.71)	<0.0001	5,717	1.42 (1.18-1.70)	<0.0001	56		
60-69	7,743	1.73 (1.44-2.08)	<0.0001	7,733	1.73 (1.44-2.08)	<0.0001	10		
70+	1,099	2.05 (1.66-2.53)	<0.0001	1,099	2.05 (1.66-2.52)	<0.0001	-		

Variable	Overall cohort (N=19,197)			Malignant disease cohort (N=18, 884)			Non-Malignant disease cohort (N=313)		
	No. cases	HR (95% CI)	P	No. cases	HR (95% CI)	P	No. cases	HR (95% CI)	P
EBMT Risk Score			<0.0001			<0.0001			0.504
<2	352	1.0		337	1.0		15	1.0	
2	4,051	1.16 (0.92-1.47)	0.204	3,912	1.17 (0.93-1.48)	0.19	139	0.48 (0.04-6.41)	0.58
3-4	13,346	1.27 (1.00-1.60)	0.048	13,187	1.27 (1.01-1.61)	0.069	159	0.71 (0.06-8.66)	0.79
>4	1,448	1.65 (1.27-2.13)	0.00040	1,448	1.65 (1.28-2.14)	0.0003	-		
Year of transplant			0.0001			<0.0001			0.15
2009	1,318	1.0		1,311	1.0		7	\	
2010	1,488	0.97 (0.87-1.08)	0.53	1,480	0.97 (0.87-1.08)	0.54	8		
2011	1,568	0.91 (0.82-1.01)	0.089	1,557	0.91 (0.82-1.01)	0.088	11	1.0	
2012	1,641	0.91 (0.82-1.01)	0.084	1,629	0.91 (0.82-1.01)	0.088	12		
2013	1,671	0.90 (0.81-1.00)	0.064	1,658	0.90 (0.81-1.01)	0.067	13		
2014	1,715	0.83 (0.75-0.93)	0.0017	1,706	0.84 (0.75-0.94)	0.0019	9	/	
2015	1,821	0.76 (0.68-0.86)	<0.0001	1,802	0.76 (0.68-0.86)	<0.0001	19	\	
2016	1,947	0.75 (0.66-0.84)	<0.0001	1,906	0.75 (0.66-0.85)	<0.0001	41		
2017	2,023	0.76 (0.67-0.86)	<0.0001	1,963	0.76 (0.67-0.86)	<0.0001	60	0.27 (0.05-1.44)	0.12
2018	1,988	0.69 (0.60-0.80)	<0.0001	1,917	0.70 (0.61-0.81)	<0.0001	71		
2019	2,017	0.73 (0.63-0.86)	0.00011	1,955	0.73 (0.62-0.86)	0.00010	62	/	

Excludes N=49 patients missing patient sex.

Supplementary Table 4b: Multivariate analysis for 5-year Overall Survival in the different subgroups – paediatric patients, malignant diagnoses only

Cohort:		Overall cohort (N=850)	
Variable	No. cases	HR (95% CI)	P
Patient ethnicity			0.11
Asian	67	1.13 (0.75-1.69)	0.56
Black	35	0.88 (0.49-1.57)	0.71
Other	59	1.30 (0.84-2.01)	0.24
White	689	1.0	
Lansky Performance Score			0.85
100	151	1.0	
90	223	1.33 (0.93-1.91)	0.12
80	160	1.25 (0.85-1.83)	0.27
≤70	41	0.99 (0.54-1.81)	0.96
missing	275	1.14 (0.80-1.62)	0.48
HCT-CI			0.49
Unknown	21	1.0	
None	578	0.73 (0.37-1.43)	0.35
Low	23	0.69 (0.25-1.90)	0.48
Intermediate/High	16	1.24 (0.47-3.30)	0.67
Missing	12	1.01 (0.50-2.04)	0.97
Diagnosis			
All other	89	1.0	
Solid tumour	761	0.85 (0.37-1.98)	0.71
Patient sex			
Male	486	1.10 (0.88-1.38)	0.40
Female	364	1.0	
Patient age			0.51
<10	648	1.0	
10-18	202	1.13 (0.84-1.51)	0.42
EBMT Risk Score			0.15
<2	775	1.0	
2	50	0.23 (0.07-0.75)	0.013
3-4	25	0.29 (0.08-1.08)	0.038
>4	-		
Year of transplant			0.071
2009	62	1.0	
2010	70	1.00 (0.61-1.64)	1.00
2011	83	1.00 (0.62-1.62)	0.99
2012	85	1.04 (0.64-1.67)	0.88
2013	65	0.88 (0.52-1.47)	0.62
2014	60	0.49 (0.27-0.89)	0.020
2015	96	0.67 (0.41-1.10)	0.11
2016	82	1.04 (0.64-1.71)	0.86
2017	86	0.92 (0.55-1.55)	0.79
2018	82	0.55 (0.31-0.98)	0.047
2019	79	0.52 (0.27-1.01)	0.054

Excludes N=4 missing patient sex and N=19 patients with non-malignant diagnoses

Supplementary Table 5: Multivariate analysis of the primary outcome of 5-year Overall Survival in the different subgroups of the allogeneic haematopoietic cell transplant cohort

Variable	Overall cohort (N=13,268) ^a			Paediatric patient cohort (N=2,212) ^b			Adult patient cohort (N=11,007) ^c		
	No. cases	HR (95% CI)	P value	No. cases	HR (95% CI)	P value	No. cases	HR (95% CI)	P value
Patient ethnicity			0.057			0.0011			0.24
Asian	995	1.16 (1.03-1.30)	0.012	384	1.67 (1.28-2.19)	0.00018	603	1.08 (0.95-1.23)	0.26
Black	402	1.13 (0.95-1.34)	0.18	156	0.91 (0.59-1.42)	0.68	243	1.20 (0.99-1.45)	0.071
Other	680	1.04 (0.92-1.18)	0.54	183	1.17 (0.84-1.62)	0.35	492	0.99 (0.86-1.15)	0.93
White	11,191	1.0		1,489	1.0		9,669	1.0	
Karnofsky or Lansky Performance Score			<0.0001			0.00093			<0.0001
100	3,506	1.0		661	1.0		2,829	1.0	
90	5,692	1.08 (1.01-1.16)	0.018	660	1.19 (0.93-1.51)	0.16	5,019	1.08 (1.01-1.16)	0.029
80	1,965	1.27 (1.17-1.38)	<0.0001	304	1.32 (1.00-1.76)	0.054	1,658	1.26 (1.16-1.38)	<0.0001
≤70	813	1.47 (1.31-1.65)	<0.0001	114	2.19 (1.52-3.15)	<0.0001	697	1.42 (1.26-1.60)	<0.0001
missing	1,292	1.12 (1.01-1.25)	0.039	473	1.30 (0.96-1.76)	0.089	804	1.11 (0.98-1.25)	0.099
Malignant disease									
Yes	11,600	2.67 (2.29-3.11)	<0.0001	1,041	3.67 (2.79-4.82)	<0.0001	10,538	2.21 (1.79-2.73)	<0.0001
No	1,668	1.0		1,171	1.0		469	1.0	
Donor type			<0.0001			0.35			<0.0001
Related donor	4,045	1.0		677	1.0		3,357	1.0	
Unrelated donor	8,240	1.17 (1.08-1.27)	<0.0001	1,152	1.23 (0.87-1.75)	0.25	7,062	1.19 (1.09-1.30)	<0.0001
Cord	533	1.08 (0.90-1.31)	0.44	269	1.34 (0.92-1.97)	0.13	252	0.79 (0.61-1.03)	0.083
Mismatched related/Haploidentical	450	0.85 (0.71-1.03)	0.094	114	1.00 (0.57-1.75)	1.00	336	0.80 (0.65-0.99)	0.038
HLA matching			<0.01			0.029			<0.0001
10/10 HLA match	9,576	1.0		1,402	1.0		8,155	1.0	
HLA mismatched	2,199	1.31 (1.21-1.41)	<0.0001	458	1.46 (1.13-1.88)	0.0035	1,737	1.29 (1.18-1.40)	<0.0001
Indeterminable	127	1.43 (1.08-1.88)	0.011	48	1.13 (0.63-2.02)	0.69	74	1.45 (1.05-2.01)	0.025
Missing	1,364	1.18 (1.07-1.30)	0.00085	304	1.10 (0.82-1.49)	0.53	1,041	1.24 (1.11-1.38)	<0.0001
Source of stem cells[‡]			0.64			0.33			0.57
BM	1,794	1.0		1,263	1.0		506	1.0	
PBSC	10,923	1.06 (0.94-1.19)	0.37	677	1.18 (0.95-1.46)	0.14	10,234	0.94 (0.81-1.08)	0.37
BM + PBSC	18	1.16 (0.60-2.26)	0.66	3	Not calculated	-	15	1.14 (0.58-2.23)	0.71
Cord	533	Not calculated	-	269	Not calculated	-	252	Not calculated	-
Conditioning regimen									
RIC	8,680	0.87 (0.81-0.94)	0.00022	467	1.09 (0.85-1.41)	0.51	8,207	0.86 (0.80-0.93)	0.00018
Myeloablative	4,588	1.0		1,745	1.0		2,800	1.0	

HCT-CI			<0.0001			0.012			<0.0001
Unknown	1,029	1.0		197	1.0		830	1.0	
None	5,991	0.88 (0.80-0.98)	0.016	1,133	0.70 (0.51-0.97)	0.034	4,827	0.90 (0.81-1.00)	0.059
Low	2,671	1.07 (0.96-1.19)	0.25	327	0.97 (0.66-1.41)	0.85	2,338	1.08 (0.97-1.22)	0.18
Intermediate/High	1,888	1.11 (0.99-1.25)	0.067	111	1.19 (0.75-1.90)	0.45	1,777	1.13 (1.00-1.27)	0.049
Missing	1,689	1.01 (0.89-1.14)	0.93	444	0.73 (0.50-1.06)	0.094	1,235	1.03 (0.91-1.18)	0.63
Patient age at Transplant			<0.0001						<0.0001
<10	1,416	1.0					0	-	-
10-19	1,072	0.97 (0.82-1.14)	0.68				227	1.0	
20-29	1,174	1.08 (0.91-1.28)	0.41				1,174	1.05 (0.81-1.36)	0.74
30-39	1,289	1.15 (0.97-1.37)	0.104				1,289	1.13 (0.87-1.46)	0.36
40-49	2,049	1.23 (1.03-1.46)	0.019				2,049	1.22 (0.94-1.58)	0.13
50-59	3,113	1.44 (1.21-1.70)	<0.0001				3,113	1.44 (1.11-1.86)	0.0059
60-69	2,896	1.81 (1.52-2.14)	<0.0001				2,896	1.81 (1.40-2.34)	<0.0001
70+	259	2.12 (1.68-2.67)	<0.0001				259	2.13 (1.58-2.87)	<0.0001
Recipient/Donor CMV matching			<0.0001			0.14			<0.0001
Pos/Pos	4,374	1.0		509	1.0		3,849	1.0	
Pos/Neg	2,391	1.17 (1.08-1.26)	<0.0001	339	1.14 (0.84-1.53)	0.41	2,042	1.16 (1.08-1.26)	0.00011
Neg/Pos	1,298	0.97 (0.88-1.07)	0.55	298	0.79 (0.57-1.09)	0.14	993	0.99 (0.89-1.10)	0.86
Neg/Neg	5,205	0.89 (0.83-0.95)	0.00034	1,066	0.90 (0.70-1.16)	0.42	4,123	0.89 (0.83-0.95)	0.00047
EBMT Risk Score			0.00012			0.52			0.00012
<2	1,194	1.0		923	1.0		250	1.0	
2	2,156	0.97 (0.83-1.14)	0.68	676	1.02 (0.81-1.30)	0.85	1,465	0.94 (0.73-1.21)	0.63
3-4	6,920	1.08 (0.92-1.26)	0.053	603	1.13 (0.88-1.44)	0.34	6,304	1.06 (0.83-1.35)	0.67
>4	2,998	1.16 (0.99-1.37)	0.0029	10	0.50 (0.12-2.09)	0.34	2,988	1.19 (0.92-1.53)	0.19
Year of transplant			<0.0001			0.028			<0.0001
2009	947	1.0		174	1.0		767	1.0	
2010	997	0.93 (0.81-1.05)	0.24	168	0.89 (0.58-1.34)	0.56	828	0.92 (0.80-1.05)	0.21
2011	1,129	0.95 (0.84-1.08)	0.42	167	0.62 (0.40-0.96)	0.031	958	0.98 (0.85-1.12)	0.73
2012	1,177	0.88 (0.77-1.00)	0.042	201	0.83 (0.55-1.24)	0.36	970	0.88 (0.77-1.01)	0.69
2013	1,276	0.83 (0.73-0.95)	0.0052	208	0.99 (0.67-1.45)	0.12	1,063	0.85 (0.74-0.97)	0.017
2014	1,325	0.82 (0.72-0.93)	0.0019	232	0.53 (0.34-0.81)	0.34	1,084	0.82 (0.72-0.94)	0.0046
2015	1,255	0.88 (0.77-1.00)	0.043	218	0.99 (0.67-1.45)	0.95	1,036	0.86 (0.75-0.99)	0.035
2016	1,315	0.79 (0.69-0.90)	0.00034	218	0.53 (0.34-0.81)	0.0037	1,092	0.81 (0.71-0.93)	0.0034
2017	1,309	0.78 (0.68-0.89)	0.00020	215	0.68 (0.44-1.05)	0.0803	1,089	0.77 (0.67-0.89)	0.0032
2018	1,237	0.76 (0.66-0.87)	<0.0001	202	0.77 (0.50-1.19)	0.23	1,031	0.74 (0.64-0.86)	<0.0001
2019	1,301	0.68 (0.59-0.78)	<0.0001	209	0.51 (0.32-0.83)	0.0065	1,089	0.69 (0.59-0.80)	<0.0001
Donor age			0.0902			0.34			0.14
Cord	533	1.0		269	1.0		252	1.0	
0-10	197	1.13 (0.81-1.57)	0.47	183	1.20 (0.78-1.84)	0.404	9	1.13 (0.42-3.02)	0.81
11-18	295	0.82 (0.65-1.04)	0.104	149	0.77 (0.47-1.26)	0.29	145	0.86 (0.65-1.13)	0.27

19-29	3,884	0.92 (0.84-1.00)	0.058	531	0.78 (0.57-1.06)	0.11	3,346	0.93 (0.85-1.02)	0.12
30-39	2,235	0.94 (0.86-1.03)	0.19	289	0.93 (0.66-1.31)	0.67	1,943	0.94 (0.86-1.04)	0.24
40-49	1,515	0.98 (0.89-1.08)	0.63	162	1.13 (0.77-1.65)	0.54	1,349	0.97 (0.88-1.08)	0.62
50-59	903	1.04 (0.93-1.17)	0.49	28	1.13 (0.53-2.39)	0.76	874	1.06 (0.94-1.19)	0.37
60+	419	1.15 (0.98-1.34)	0.089	3	Not calculated	-	416	1.18 (1.01-1.39)	0.037
missing	3,287	Not calculated	-	598	Not calculated	-	2,673	Not calculated	-
T cell depletion						0.88			0.022
None	-	-	-	528	1.0		2,749	1.0	
Alemtuzumab	-	-	-	1,164	0.93 (0.70-1.24)	0.62	6,712	0.91 (0.85-0.99)	0.020
ATG or ALG	-	-	-	520	0.96 (0.72-1.29)	0.78	1,546	0.99 (0.90-1.09)	0.83
Donor/Recipient Sex match						0.046			
Male/Male				853	1.0				
Male/Female				545	1.36 (1.08-1.70)	0.0084			
Female/Male				462	1.27 (0.98-1.64)	0.069			
Female/Female				352	1.27 (0.97-1.66)	0.0804			

± BM – Bone Marrow, PBSC – Peripheral Blood Stem Cells

Excludes a) 710, b) 278 and c) 481 patients from each respective analysis where outcome data for one or more variables included in the model were missing, thus precluding analysis.

Bold text denotes significant P-values

Supplementary Table 6: Summary of multivariate analyses determining associations between patient ethnicity and clinical outcome variables for the overall allogeneic haematopoietic cell transplant cohort, and both the adult and paediatric subgroups. Covariates for the overall cohort analyses included Karnofsky/Lansky score, donor type, HLA Matched, EBMT risk score, patient age at transplant, CMV serostatus match, (non)-malignant disease, year of transplant, donor age and source of stem cells for all analyses, plus type of conditioning regimen for all but TRM at 100 days, HCT-CI for all but aGvHD, patient and donor sex match for all but OS and all TRM analyses, and T cell depletion for only aGvHD analysis.

Covariates for the paediatric cohort analyses included Karnofsky/Lansky score, HLA Matched, EBMT risk score, (non)-malignant disease, year of transplant and T cell depletion for all analyses, plus patient age for all but OS, CMV matched for all but PFS, donor age, donor type, source of stem cells for all but Relapse, type of conditioning regimen for all but TRM, HCT-CI for all but PFS and aGvHD, patient and donor sex match for all but PFS and Relapse analysis.

Covariates for the adult cohort analyses included Karnofsky/Lansky score, HLA Matched, EBMT risk score, (non)-malignant disease, year of transplant, source of stem cells, CMV matched, type of conditioning regimen, donor type and donor age for all analyses, plus HCT-CI and patient age for all but aGvHD, patient and donor sex match for all but OS, and T cell depletion for all but TRM analysis.

Outcome	Variable	Overall			Paediatric cohort			Adult cohort		
		No. of cases	Hazard Ratio (95% CI)	P value	No. of cases	Hazard Ratio (95% CI)	P value	No. of cases	Hazard Ratio (95% CI)	P value
5-year Overall Survival	* Overall			0.057			0.0011			0.24
	Asian	995	1.16 (1.03-1.30)	0.012	384	1.67 (1.28-2.19)	0.00018	603	1.08 (0.95-1.23)	0.26
	Black	402	1.13 (0.95-1.34)	0.18	156	0.91 (0.59-1.42)	0.68	243	1.20 (0.99-1.45)	0.071
	Other	680	1.04 (0.92-1.18)	0.54	183	1.17 (0.84-1.62)	0.35	492	0.99 (0.86-1.15)	0.93
	White	11,191	1.0		1,489	1.0		9,669	1.0	
5-year PFS	* Overall			0.053			0.011			0.36
	Asian	979	1.14 (1.02-1.27)	0.019	415	1.44 (1.15-1.81)	0.0014	595	1.06 (0.94-1.20)	0.35
	Black	391	1.05 (0.89-1.24)	0.59	171	1.00 (0.70-1.41)	0.98	235	1.12 (0.93-1.34)	0.25
	Other	671	1.11 (0.99-1.24)	0.086	205	1.19 (0.91-1.55)	0.21	488	1.08 (0.95-1.23)	0.22
	White	11,057	1.0		1,604	1.0		9,568	1.0	
100 day TRM	* Overall			<0.0001			0.014			<0.0001
	Asian	1,024	1.94 (1.56-2.40)	<0.0001	404	2.18 (1.36-3.48)	0.0012	595	1.93 (1.50-2.48)	<0.0001
	Black	404	1.88 (1.38-2.57)	<0.0001	161	1.48 (0.71-3.09)	0.29	231	2.13 (1.49-3.04)	<0.0001
	Other	690	1.51 (1.16-1.96)	0.0021	192	1.25 (0.64-2.43)	0.52	477	1.57 (1.17-2.10)	0.0027
	White	11,143	1.0		1,522	1.0		9,439	1.0	

1-year TRM	* Overall			<0-0001			0-00083			0.00026
	Asian	991	1.52 (1.29-1.80)	<0-0001	404	2.05 (1.44-2.94)	<0-0001	595	1.43 (1.18-1.74)	0.00035
	Black	397	1.37 (1.06-1.76)	0-017	161	1.17 (0.66-2.07)	0.603	231	1.44 (1.07-1.94)	0-016
	Other	669	1.22 (1.01-1.48)	0-042	192	1.10 (0.66-1.82)	0.72	477	1.24 (1.00-1.53)	0-047
	White	11,054	1.0		1,522	1.0		9,439	1.0	
5-year TRM	* Overall			<0-0001			0.00103			0.00027
	Asian	991	1.46 (1.26-1.69)	<0-0001	404	1.94 (1.40-2.69)	<0-0001	595	1.40 (1.19-1.66)	<0-0001
	Black	397	1.29 (1.03-1.62)	0-029	161	1.16 (0.69-1.93)	0.58	231	1.33 (1.03-1.73)	0-032
	Other	669	1.15 (0.97-1.36)	0.11	192	1.20 (0.78-1.85)	0.40	477	1.12 (0.93-1.34)	0.25
	White	11,054	1.0		1,522	1.0		9,439	1.0	
5-year Relapse	* Overall			0.56			0.26			0.52
	Asian	975	0.94 (0.81-1.09)	0.39	388	1.23 (0.87-1.73)	0.25	595	0.90 (0.76-1.06)	0.20
	Black	386	0.90 (0.72-1.14)	0.39	159	0.65 (0.35-1.20)	0.17	231	0.98 (0.76-1.26)	0.87
	Other	660	1.06 (0.91-1.24)	0.47	188	1.12 (0.77-1.64)	0.55	477	1.06 (0.90-1.26)	0.49
	White	10,923	1.0		1,518	1.0		9,439	1.0	
aGvHD (grade 2-4)	* Overall			0.18			0.91			0.062
	Asian	919	0.84 (0.70-1.02)	0.081	371	0.93 (0.67-1.28)	0.64	548	0.77 (0.61-0.99)	0-038
	Black	369	0.79 (0.59-1.06)	0.12	148	0.86 (0.53-1.41)	0.55	221	0.71 (0.49-1.03)	0.072
	Other	612	0.94 (0.77-1.16)	0.57	172	1.01 (0.68-1.50)	0.95	440	0.90 (0.70-1.15)	0.39
	White	10,423	1.0		1,456	1.0		8,967	1.0	

Bold text denotes significant P-values

Supplementary Table 7: Summary of multivariate analyses determining associations between patient ethnicity and clinical outcome variables in the malignant and non-malignant subgroups of both the paediatric and adult allogeneic haematopoietic cell transplant cohorts.

Outcome	Variable	Paediatric – Malignant			Paediatric – Non-malignant			Adult – Malignant			Adult – Non-malignant ‡		
		No. of cases	Hazard Ratio (95% CI)	P value	No. of cases	Hazard Ratio (95% CI)	P value	No. of cases	Hazard Ratio (95% CI)	P value	No. of cases	Hazard Ratio (95% CI)	P value
5-year OS	* Overall			0.028			0.054			0.29			0.34
	Asian	89	1.68 (1.18-2.40)	0.0044	295	1.78 (1.11-2.84)	0.016	556	1.05 (0.92-1.21)	0.46	47	1.76 (0.87-3.58)	0.12
	Black	37	0.85 (0.46-1.58)	0.61	119	1.25 (0.62-2.52)	0.53	225	1.20 (0.99-1.46)	0.068	18	1.51 (0.45-5.11)	0.51
	Other	79	1.02 (0.68-1.53)	0.94	104	1.91 (1.06-3.47)	0.032	465	1.00 (0.86-1.15)	0.94	27	0.75 (0.29-1.95)	0.56
	White	836	1.0		653	1.0		9,292	1.0		377	1.0	
5-year PFS	* Overall			0.11			0.078			0.37			0.33
	Asian	97	1.47 (1.08-2.01)	0.015	318	1.51 (1.05-2.16)	0.025	548	1.04 (0.92-1.18)	0.53	47	1.63 (0.80-3.33)	0.18
	Black	48	0.99 (0.63-1.56)	0.96	123	1.18 (0.66-2.09)	0.58	217	1.12 (0.93-1.36)	0.23	18	1.59 (0.48-5.25)	0.44
	Other	89	1.09 (0.78-1.52)	0.61	116	1.62 (1.01-2.59)	0.044	461	1.09 (0.96-1.24)	0.19	27	0.66 (0.26-1.71)	0.39
	White	902	1.0		702	1.0		9,192	1.0		376	1.0	
100 day TRM	* Overall			0.27			0.102			<0.0001			0.63
	Asian	92	1.92 (0.91-4.06)	0.087	312	2.30 (1.18-4.47)	0.014	548	1.96 (1.51-2.55)	<0.0001	47	2.37 (0.62-9.14)	0.21
	Black	38	1.33 (0.41-4.26)	0.64	123	1.71 (0.62-4.71)	0.29	213	2.22 (1.54-3.20)	<0.0001	18	1.81 (0.23-14.48)	0.58
	Other	81	0.73 (0.25-2.17)	0.57	111	1.93 (0.78-4.79)	0.16	450	1.57 (1.16-2.13)	0.0037	27	0.97 (0.22-4.29)	0.96
	White	843	1.0		679	1.0		9,071	1.0		368	1.0	
1-year TRM	* Overall			0.00087			0.41			0.00059			0.21
	Asian	92	2.62 (1.57-4.38)	0.00025	312	1.49 (0.89-2.48)	0.13	548	1.39 (1.14-1.71)	0.0014	47	2.65 (0.93-7.57)	0.068
	Black	38	1.04 (0.40-2.75)	0.93	123	1.23 (0.58-2.62)	0.59	213	1.47 (1.09-2.00)	0.012	18	1.72 (0.27-10.93)	0.57
	Other	81	0.68 (0.30-1.53)	0.35	111	1.56 (0.79-3.10)	0.20	450	1.25 (1.01-1.55)	0.045	27	0.67 (0.19-2.40)	0.54
	White	843	1.0		679	1.0		9,071	1.0		368	1.0	
5-year TRM	* Overall			0.0065			0.17			0.0010			0.11
	Asian	92	2.26 (1.41-3.64)	0.00076	312	1.62 (1.00-2.62)	0.048	548	1.36 (1.14-1.62)	0.00064	47	2.6 (1.02-5.01)	0.046
	Black	38	1.06 (0.46-2.41)	0.89	123	1.27 (0.62-2.57)	0.52	213	1.38 (1.05-1.80)	0.019	18	0.95 (0.18-5.08)	0.95
	Other	81	0.95 (0.52-1.75)	0.88	111	1.74 (0.92-3.29)	0.091	450	1.12 (0.93-1.36)	0.23	27	0.63 (0.21-1.87)	0.41
	White	843	1.0		679	1.0		9,071	1.0		368	1.0	
5-year Relapse	* Overall			0.63			0.42			0.43			0.95
	Asian	90	1.21 (0.78-1.87)	0.39	298	0.94 (0.48-1.82)	0.84	548	0.88 (0.74-1.05)	0.15	47	1.02 (0.25-4.09)	0.98
	Black	38	0.73 (0.35-1.51)	0.39	121	0.35 (0.10-1.26)	0.11	213	0.97 (0.75-1.26)	0.83	18	0.65 (0.09-4.91)	0.68
	Other	81	1.09 (0.71-1.66)	0.702	107	1.10 (0.46-2.63)	0.82	450	1.06 (0.90-1.26)	0.49	27	1.33 (0.26-7.59)	0.75
	White	850	1.0		668	1.0		9,071	1.0		368	1.0	

aGvHD (grade 2-4)	* Overall			0.92			0.602			0.051			0.69
	Asian	85	1.18 (0.71-1.95)	0.52	286	0.79 (0.50-1.26)	0.32	508	0.77 (0.60-0.99)	0.041	40	0.60 (0.10-3.66)	0.58
	Black	32	0.92 (0.42-2.04)	0.84	116	0.70 (0.36-1.39)	0.31	203	0.68 (0.46-1.00)	0.047	18	1.35 (0.07-25.55)	0.84
	Other	76	1.01 (0.59-1.71)	0.98	96	1.04 (0.56-1.94)	0.903	414	0.91 (0.71-1.16)	0.44	26	0.27 (0.02-3.08)	0.29
	White	818	1.0		638	1.0		8,612	1.0		355	1.0	

Bold text denotes significant P-values

± Subgroup sizes for these analyses appear to be too small for meaningful interpretation as evidenced by the 95% Confidence Intervals.